Last reviewed · How we verify
Endocrine
At a glance
| Generic name | Endocrine |
|---|---|
| Also known as | Varies |
| Sponsor | Baylor Breast Care Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer (NA)
- Natural History Study of Children and Adults With Medullary Thyroid Cancer
- Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients (PHASE3)
- A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy. (PHASE3)
- Pilot Study of Continuous Glucose Monitoring for Postpartum Glucose Screening (NA)
- AMH Dynamic Changes to Predict Ovarian Reserve in Perimenopausal Breast Cancer
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (PHASE3)
- Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Endocrine CI brief — competitive landscape report
- Endocrine updates RSS · CI watch RSS
- Baylor Breast Care Center portfolio CI